However, ruxolitinib was also able to significantly inhibit SEB-induced production of pro-inflammatory cytokines, especially Th1 cytokines such as IL-6, IL-12, and IFN-γ itself, both in vitro and in vivo (either prophylactic or immediately after induction of CRS). This evidence concerns the gene IL6 and congenital rubella syndrome.